Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benserazide - Phoenicia Biosciences

Next Previous
X
Search
Drug Profile

Benserazide - Phoenicia Biosciences

Alternative Names: PB 04

Latest Information Update: 19 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenicia Biosciences
  • Class Antiparkinsonians; Hydrazines
  • Mechanism of Action Decarboxylase inhibitors; Fetal haemoglobin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 10 Dec 2022 Pharmacodynamics data from a preclinical study in Beta-thalassaemia and Sickle cell anaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 23 Jun 2020 Benserazide - Phoenicia Biosciences is available for licensing as of 23 Jun 2020. https://phbiosci.com/pb04.html
  • 22 Jun 2020 Phoenicia BioScience plans a phase I/II trial for Beta Thalassemia and Sickle Cell anemia in USA and Canada (PO) in August 2020 (NCT04432623)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top